SEC Form 4 · accession 0001140361-17-022461
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Louis W Sullivan
Director
Period of report
May 25, 2017
Accepted (ET)
May 26, 2017 · 1:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2016 | J | 152 | $0.00 | A | 34,637 | D | |
| Common StockF2 | Aug 1, 2016 | J | 604 | $0.00 | A | 35,241 | D | |
| Common StockF3 | Aug 1, 2016 | J | 577 | $0.00 | A | 35,818 | D | |
| Common StockF4,F5 | May 25, 2017 | A | 8,259 | $0.00 | A | 40,077 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to buy)F6,F7 | $14.71 | Aug 1, 2016 | J | 693 | A | — | May 20, 2020 | Common Stock | 7,893 | 7,893 | D |
| Employee Stock Option (Right to buy)F6,F7 | $20.08 | Aug 1, 2016 | J | 693 | A | — | May 19, 2021 | Common Stock | 7,893 | 7,893 | D |
| Employee Stock Option (Right to buy) (Common Stock)F6,F7 | $13.37 | Aug 1, 2016 | J | 693 | A | — | May 17, 2019 | Common Stock | 7,893 | 7,893 | D |
| Employee Stock Option (Right to buy) (Common Stock)F6,F7 | $13.00 | Aug 1, 2016 | J | 693 | A | — | May 23, 2020 | Common Stock | 7,893 | 7,893 | D |
| Employee Stock Option (Right to buy) (Common Stock)F6 | $18.64 | Aug 1, 2016 | J | 905 | A | May 22, 2017 | May 22, 2021 | Common Stock | 10,305 | 10,305 | D |
Explanation of responses
- F1In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
- F2In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
- F3In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
- F4Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- F5These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date.
- F6Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
- F7The option grant is fully vested.